company held the first half of the board of directors and the board of supervisors

semi-annual performance reached a record high

news 8# November 29 , the group company held the 10th board of directors 11 meeting by means of communication, deliberated and passed the "Jianfeng Group 2019 Semi-Annual Report", "On the company's internal control system amendment" and other proposals.

In the first half of the year, the company focused on the general work policy of "innovation and reform, integration and improvement, scientific layout, and steady development " , and focused on the optimization of economic structure and industrial upgrading. Opportunities, continuous internal resource integration, improvement of internal management system, and improvement of enterprise operation efficiency. In the first half of 2019 , the company realized total operating income of 16.86 .9 billion yuan, up 12.17% year-on-year, net profit attributable to owners of the parent company 4.76 .3 billion yuan, up 57.55% year-on-year, and the semi-annual operating performance reached a record high. As of the end of 2019 6 , the company's total assets were 53.83 .1 billion yuan, up 9.82 from the beginning of the year ; Net assets were 38.17 .5 billion yuan, up 10.64 from the beginning of the year .

In the first half of the year, the company made a new breakthrough in the expansion of cement business. The group company completed the acquisition of 100% equity of Guizhou huangpinggu longmingchuan cement co., ltd. and continued to invest in the construction of its new dry cement production line with a daily production of 4500 tons of cement clinker (with waste heat power generation); Yunnan Jianfeng invested ,500 yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd, the company plans to build a cement clinker production line in Mengla County, Xishuangbanna Dai Autonomous Prefecture in accordance with relevant national policies. The company's cement subsidiaries continue to carry out in-depth "three down three improve " activities, steadily implement standardized management, while strictly controlling production costs, and continuously improve labor productivity. Daye Peak, in accordance with the spirit of the Group's standardization year, has implemented standardization of production site management and has achieved good results. Comprehensive treatment of cement packaging dust, hydraulic system of limestone stacker, cement cooling commissioning and other technical renovation projects have been carried out in an orderly manner, all of which have reached good expectations. Yunnan Jianfeng timely grasps the price changes of related products of upstream suppliers through various channels, and strictly controls the procurement cost of raw materials. Concentrate on the development of market share in the core region as a key work, constantly explore and formulate sales strategies suitable for the regional market, effectively improve the market popularity and share of Jianfeng Cement, and achieve the best business performance since it was put into production.

Jianfeng Pharmaceutical continued to increase investment in drug research and development and obtained the Drug Registration Approval for Olopatadine Hydrochloride Eye Drops. In the face of changes in the pharmaceutical sales environment, Spike Pharmaceuticals has integrated its pharmaceutical business and pharmaceutical retail, and strived to extend and expand its third-end market share. Accelerate the consistency evaluation of related drugs, and lay a good foundation for the next step to participate in the centralized procurement of drugs. Jianfeng Pharmaceutical and its subsidiaries continue to increase investment in safety and environmental protection, improve and upgrade various safeguards, and improve the level of automatic control of equipment and facilities; adhere to prevention, improve safety management and three waste treatment capabilities, and effectively reduce environmental protection and safety Production risk. In the first half of the year, Jianfeng Pharmaceutical and its subsidiaries made new progress in a number of technological innovations and engineering constructions. Jianfeng Pharmaceutical's international project of annual production of 20 .7 billion solid preparations has obtained EIA approval and completed civil engineering and bidding for some equipment. Shanghai Beika Drug Approval R & D Laboratory Renovation Project has entered the stage of equipment installation and commissioning. A number of technological transformation projects in Anhui Beika have been carried out in an orderly manner, environmental protection transformation projects such as waste gas (RTO ) and sewage treatment have been put into operation, and the annual output of 1500 tons of acetamiprid powder in pesticide preparation workshop has entered the trial production stage. The laboratory renovation of GMP of Anhui Zhongwang Small Molecule Targeted Drug Research Institute has been basically completed, and the second phase technical renovation project of GMP workshop, including common drugs and small molecule targeted antitumor drugs, has obtained government approval.

The production and operation activities of other business segments of the company are carried out in a standardized and orderly manner.

On the same day, the company also held the rd meeting of the 9th Board of Supervisors and reviewed and approved the relevant report. (Yu fruit)